Brain stimulation studied for Parkinson's
Posted on: Monday, 19 January 2009, 12:13 CST
Researchers in Alabama say electronic deep brain stimulation is effective in both older and younger people who have Parkinson's disease.
Researchers at the University of Alabama in Birmingham spent six years studying 255 Parkinson's patients, including older patients who had previously been excluded from such research, The Birmingham (Ala.) News reported Monday.
Implanting electrodes to stimulate the brain proved significant for a wide range of patients who no longer responded well to medication, said Dr. Barton L. Guthrie, a UAB neurosurgeon.
In the study of patients 37 to 83 years old, 71 percent of patients who received deep brain stimulation showed significant gain in motor functions as compared with 32 percent given only drugs.
The most common side effects from the stimulation were infections, pain, depression and balance problems, most of which were resolved during the study, Guthrie said, noting there was one death.
Parkinson's is neurodegenerative condition marked by tremors and lack of coordination.
Source: United Press International
Related Articles
- Urate In Blood And Spinal Fluid May Predict Slower Decline In Patients With Parkinson's Disease
- ProteoTech Receives Funding From The Michael J. Fox Foundation for Parkinson's Disease Research to Develop Tolls for Imaging Alpha-Synuclein Aggregation in Living Parkinson's Brain
- Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival
- ACADIA Pharmaceuticals Initiates Second Phase III Trial With Pimavanserin in Patients With Parkinson's Disease Psychosis
- ACADIA Pharmaceuticals Initiates Phase III Trial With Pimavanserin in Patients With Parkinson's Disease Psychosis
- New Study Reveals Investigational 24-Hour Formulation of Requip(R) (Ropinirole HCl) Tablets Reduced "Off" Time for Patients With Parkinson's Disease
- Valeant Pharmaceuticals Receives FDA Approval of Zelapar(R) for Patients With Parkinson's Disease; Zelapar Significantly Reduces ``Off'' Time Through Unique Delivery Mechanism
- ACADIA Pharmaceuticals Announces Positive Results From Phase II Trial of ACP-103 for Treatment-Induced Psychosis in Patients With Parkinson's Disease
- Kids' Chess Contest 'Stimulates Their Brain'
- Neurologix Announces Positive Interim Results of Landmark Gene Therapy Clinical Trial for Patients With Parkinson's Disease
 |
 |
User Comments (0)
RSS Feeds